Delcath Systems

Delcath Systems is a specialty pharmaceutical and medical device company focused on oncology. Its proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

History

Delcath Systems was founded in 1988 and is headquartered in Queensbury, New York. The company's initial public offering was in 2000.

Products

Delcath's primary product is the Melphalan/HDS system. This system is designed to deliver high-dose chemotherapy directly to the liver, while controlling systemic exposure to the drug. This is intended to allow for higher doses of chemotherapy to be used, potentially improving efficacy while reducing systemic side effects.

Clinical Trials

Delcath Systems has conducted several clinical trials to evaluate the safety and efficacy of the Melphalan/HDS system. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates.

Regulatory Status

The Melphalan/HDS system is currently approved for use in Europe and is under review by the FDA in the United States.

Financials

As of 2020, Delcath Systems reported revenues of $2.8 million, a net loss of $16.7 million, and had $23.1 million in cash and cash equivalents.

See Also

• Chemotherapy
• Liver cancer
• Oncology